Canaccord Genuity Maintains Hold on Edwards Lifesciences, Lowers Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained a Hold rating on Edwards Lifesciences but lowered the price target from $77 to $66, indicating a more cautious outlook on the stock.
October 07, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Canaccord Genuity has maintained a Hold rating on Edwards Lifesciences but lowered the price target from $77 to $66, suggesting a more cautious outlook on the stock.
The lowering of the price target from $77 to $66 by Canaccord Genuity indicates a less optimistic view on Edwards Lifesciences' future performance. This could lead to a negative short-term impact on the stock price as investors may adjust their expectations accordingly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100